煙霧病市場規模、佔有率和成長分析：按治療方法、診斷方法、患者群體、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球 Moyamoya 病市場價值為 6.421 億美元，預計到 2033 年將從 2025 年的 6.7485 億美元成長至 10.047 億美元，在預測期（2026-2033 年）內以 5.1% 的複合年成長率。

受全球診斷能力提升和檢出率提高的推動，煙霧病市場正經歷顯著成長，進而帶動了對外科手術干預需求的不斷成長。這種進行性性腦血管疾病的特徵是顱內動脈狹窄和側支循環脆弱，需要採用包括診斷、重組手術、介入神經放射學和藥物治療在內的多方面綜合治療方法。患者，尤其是兒童和青少年，面臨嚴重的中風和長期殘疾風險，這給臨床和經濟帶來了巨大的挑戰。高解析度影像和微創技術等科技進步，以及臨床意識的提高，正在推動先進診斷方法和重組治療的普及。此外，對標靶治療和診斷創新技術的持續投入，正在為新興市場創造機遇，並改善醫療服務的可近性。

全球煙霧病市場成長要素

全球煙霧病市場成長的驅動力主要來自臨床醫生和公眾對該疾病認知度的提高，以及影像診斷技術的普及。這使得早期診斷和轉診至專科醫生變得更加順暢。隨著神經科和基層醫療專業人員對該疾病的認知不斷加深，介入放射學和神經外科的診療路徑正在逐步建立，醫療機構也在加強培訓計畫和基礎設施建設。這種全面的診斷方法透過增加接受評估和治療的患者數量來促進市場成長，從而推動了藥物治療、外科重組以及在各種醫療環境中使用不同器械進行的介入治療的需求。

全球煙霧病市場面臨的限制因素

全球煙霧病市場面臨嚴峻挑戰，主要原因是具備診斷和治療該疾病豐富經驗的臨床醫生數量有限。這種短缺限制了患者獲得專科治療的機會，尤其是在大型學術機構以外的地區，造成轉診流程受阻，延誤了必要的治療。訓練有素的神經外科醫生和介入專家的匱乏阻礙了多學科診療計畫的開展，導致區域醫療資源匱乏和病患容量有限。因此，這些臨床能力的限制阻礙了小規模醫院對必要基礎設施和技術的投資，儘管臨床需求明確，但先進的診斷工具、外科手術和後續護理卻無法廣泛應用。

煙霧病全球市場趨勢

全球煙霧病市場正經歷顯著的發展趨勢，這主要得益於影像技術和診斷方案的進步。先進的影像技術，例如精密的血管造影術和功能性影像，大大提高了早期檢測和診斷的準確性，從而為個人化治療策略提供了至關重要的支援。標準化診斷流程的引入促進了有效的多學科協作，並有助於快速做出臨床決策。此外，非侵入性篩檢技術的創新使醫療專業人員能夠追蹤疾病進展並最佳化手術時機。這種不斷發展的格局不僅支持臨床管理，也促進了臨床研究領域的合作，為全球新治療方法的開發鋪平了道路。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球煙霧病市場規模：依治療類型分類

• 藥物和藥物治療
  • 鈣離子通道阻斷劑
  • 抗血小板藥物
  • 抗凝血物
• 手術治療
  • 直接重組
  • 間接重組
• 其他

全球煙霧病市場規模：依診斷類型分類

• 磁振血管造影術
• CT血管攝影檢查
• 數位減影血管造影術
• 其他

全球煙霧病市場規模：按患者群體分類

• 兒童患者
• 成年患者
• 其他

全球煙霧病市場規模：依最終用戶分類

• 醫院
• 專科神經科中心
• 門診手術中心
• 其他

全球煙霧病市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球煙霧病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Medtronic
• Johnson & Johnson（Ceremonial/Codman）
• Stryker
• Penumbra
• MicroVention（Terumo）
• Integra LifeSciences
• Mizuho Medical
• B. Braun
• Karl Storz
• KLS Martin
• Aesculap
• Pfizer
• Bayer
• Novartis
• Sanofi
• Bristol Myers Squibb
• Takeda Pharmaceutical
• Abbott Laboratories
• Boston Scientific
• Zeiss（Carl Zeiss Meditec）

結論與建議

Global Moyamoya Disease Market size was valued at USD 642.1 Million in 2024 and is poised to grow from USD 674.85 Million in 2025 to USD 1004.7 Million by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).

The moyamoya disease market is experiencing significant growth driven by enhanced diagnostic capabilities and increased detection rates globally, leading to a higher demand for surgical interventions. This progressive cerebrovascular condition, marked by the narrowing of intracranial arteries and fragile collateral vessels, necessitates a multifaceted approach that includes diagnostics, revascularization surgeries, neurointerventional devices, and pharmacotherapy. As patients, particularly children and young adults, face serious risks like stroke and long-term disabilities, the associated clinical and economic challenges are substantial. Technological advancements, such as high-resolution imaging and minimally invasive techniques, along with increased clinical awareness, propel the uptake of advanced diagnostics and revascularization treatments. Furthermore, ongoing investment in targeted therapies and diagnostic innovations is fostering opportunities in emerging markets, enhancing care accessibility.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Moyamoya Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Moyamoya Disease Market Segments Analysis

Global moyamoya disease market is segmented by treatment type, diagnosis type, patient demographic, end-user, distribution channel and region. Based on treatment type, the market is segmented into Drugs and Pharmacological Treatment, Surgical Procedures and Others. Based on diagnosis type, the market is segmented into Magnetic Resonance Angiography, Computed Tomography Angiography, Digital Subtraction Angiography and Others. Based on patient demographic, the market is segmented into Pediatric Patients, Adult Patients and Others. Based on end-user, the market is segmented into Hospitals, Specialized Neurology Centers, Ambulatory Surgical Centers and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Moyamoya Disease Market

The Global Moyamoya Disease market is driven by heightened awareness among clinicians and the public, coupled with enhanced access to diagnostic imaging, which facilitates earlier diagnosis and more consistent referrals to specialized care. As neurologists and primary care healthcare providers increasingly recognize the condition, established pathways to interventional radiology and neurosurgery are emerging, leading healthcare organizations to enhance their training and infrastructure. This expanded approach to diagnosis bolsters market growth by increasing the number of patients undergoing evaluation and treatment, subsequently driving demand for medical management, surgical revascularization, and various device-based interventions throughout diverse healthcare environments.

Restraints in the Global Moyamoya Disease Market

The Global Moyamoya Disease market faces significant challenges due to a limited number of clinicians possessing extensive expertise in diagnosing and treating the condition. This scarcity restricts access to specialized care, particularly in regions outside major academic institutions, resulting in bottlenecks in referral processes that delay necessary treatments. The lack of trained neurosurgeons and interventional specialists hampers the development of multidisciplinary care programs, leading to reduced geographical availability and limited patient throughput. Consequently, this constrained clinical capacity deters investment in essential infrastructure and technologies at smaller hospitals, ultimately hindering the broader adoption of advanced diagnostic tools, surgical procedures, and follow-up care, despite the evident clinical need.

Market Trends of the Global Moyamoya Disease Market

The global Moyamoya disease market is witnessing a notable trend driven by advancements in imaging technologies and diagnostic protocols. Enhanced imaging modalities, such as advanced angiography and functional imaging, are significantly improving early detection and diagnostic accuracy, which crucially supports personalized treatment strategies. The implementation of standardized diagnostic pathways fosters effective multidisciplinary care coordination, enabling prompt clinical decisions. Additionally, innovations in noninvasive screening methods are empowering healthcare providers to track disease progression and optimize surgical timing. This evolving landscape not only aids clinical management but also fosters collaborations in clinical research, paving the way for the development of novel therapeutic approaches worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Moyamoya Disease Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Drugs and Pharmacological Treatment
  • Calcium Channel Blockers
  • Antiplatelet Agents
  • Anticoagulants
• Surgical Procedures
  • Direct Revascularization
  • Indirect Revascularization
• Others

Global Moyamoya Disease Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Magnetic Resonance Angiography
• Computed Tomography Angiography
• Digital Subtraction Angiography
• Others

Global Moyamoya Disease Market Size by Patient Demographic & CAGR (2026-2033)

• Market Overview
• Pediatric Patients
• Adult Patients
• Others

Global Moyamoya Disease Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialized Neurology Centers
• Ambulatory Surgical Centers
• Others

Global Moyamoya Disease Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Moyamoya Disease Market Size & CAGR (2026-2033)

• North America (Treatment Type, Diagnosis Type, Patient Demographic, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Diagnosis Type, Patient Demographic, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Diagnosis Type, Patient Demographic, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Diagnosis Type, Patient Demographic, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Diagnosis Type, Patient Demographic, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Ceremonial/Codman)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penumbra
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroVention (Terumo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mizuho Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karl Storz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KLS Martin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aesculap
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zeiss (Carl Zeiss Meditec)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations